CG66 Type 2 diabetes: full guideline
Clarification: Recommendation 81 Full guideline
This wording should not be read as implying that treatment might be aimed at achieving a low HDL cholesterol level. The intention here is to set limits for the validity of total cholesterol level measurement, not to set any kind of target for HDL cholesterol, which is usually regarded as protective against cardiovascular disease. Total cholesterol measurement is problematic as it includes HDL cholesterol, and so can be elevated by higher levels of HDL cholesterol. In these circumstances, treatments aimed at lowering total cholesterol further are not indicated and LDL cholesterol levels should be used to assess the results of lipid-lowering treatments.
MHRA advice on aspirin
The Medicines and Healthcare products Regulatory Authority (MHRA) Drug safety update (Volume 3, Issue 3, October 2009) gives the following advice on using aspirin for the primary prevention of vascular events, which is relevant to recommendations R90 and R91 in the full guideline:
Aspirin is not licensed for the primary prevention of vascular events. If aspirin is used in primary prevention, the balance of benefits and risks should be considered for each individual, particularly the presence of risk factors for vascular disease (including conditions such as diabetes) and the risk of gastrointestinal bleeding.
This page was last updated: 26 January 2011